Last reviewed · How we verify
YM178
YM178 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
YM178 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | YM178 |
|---|---|
| Also known as | mirabegron, Mirabegron |
| Sponsor | Astellas Pharma Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, YM178 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity (PHASE3)
- TReating Incontinence for Underlying Mental and Physical Health (PHASE4)
- Double j Stent Related Symptoms (EARLY_PHASE1)
- Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children (PHASE3)
- Mirabegron in Patients With Age-Related Macular Degeneration
- The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YM178 CI brief — competitive landscape report
- YM178 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI